GlassScriptPhysician profile
Anthony C Vanvreede
NPI 1871851105
$1,406.76
in general payments reported to CMS, 2019-2025
14 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.90 · 2021: $72.11 · 2022: $54.22 · 2023: $317 · 2024: $262 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.55 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $512.49 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $295.85 | 2022-2025 | Rinvoq |
| Genzyme Corporation | $98.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.98 | 2024-2025 | Sotyktu, Sprycel |
| Galderma Laboratories, L.P. | $79.69 | 2025 | Nemluvio |
| Amgen INC. | $60.01 | 2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $51.38 | 2022-2025 | |
| Medtronic, INC. | $49.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $48.81 | 2024 | Dupixent |
| Organon LLC | $24.29 | 2025 | Vtama, Hadlima |
| Merz North America, INC. | $24.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.17 | 2019 | |
| Novo Nordisk INC | $22.90 | 2021 | |
| Dermavant Sciences, INC. | $18.71 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Vanvreede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.